At a glance
ClinicalIndex Comparison Record- ✓Enrolled in the lymphangioleiomyomatosis natural history protocol
- ✓Symptoms attributed to lymphangioleiomyomas
- ✓Symptoms attributed to chylous pleural effusions
- ✓Symptoms attributed to peripheral lymphedema
- ✕Hypersensitivity to somatostatin, octreotide, or octreotide analogues
- ✕Hepatitis B, hepatitis C, or other clinically significant liver disease
- ✕Transplant recipient status
- ✕Pregnancy or breastfeeding
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
In Brief
A Phase 2 clinical trial evaluating Octreotide for Lymphangioleiomyomatosis and 3 related conditions. Completed, enrolled 4 participants across 1 site.
Detailed Summary
Lymphangioleiomyomatosis (LAM), a disease primarily of women of child-bearing age, is characterized by cystic lung disease and abdominal tumors (e.g., angiomyolipomas). Within the LAM patient population is a subset of patients who develop chylous effusions and lymphangioleiomyomas. Treatment of many of these symptoms has been ineffective. Previous studies with somatostatin and octreotide in other clinical settings have shown reduction in chylous effusions. This study assesses the effectiveness of octreotide in symptomatic patients with LAM, lymphangioleiomyomas and/or chylous effusions/ascites, peripheral lymphedema and chyluria.
Study Details
Timeline
Interventions
Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.